Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumors.
Journal: PloS one
Published: November 17, 2023
Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay.
Journal: Frontiers in oncology
Published: May 15, 2023
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
Journal: European urology
Published: December 22, 2022
A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.
Journal: European urology oncology
Published: August 15, 2022
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Journal: Nature
Published: December 08, 2020
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: September 22, 2020
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 11, 2020
Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.
Journal: The Lancet. Oncology
Published: January 03, 2020
Current challenges in the management of breast cancer brain metastases.
Journal: Seminars in oncology
Published: June 29, 2017
Immunotherapy: a new treatment paradigm in bladder cancer.
Journal: Current opinion in oncology
Published: March 18, 2017
ANG1005 for breast cancer brain metastases: correlation between 18F-FLT-PET after first cycle and MRI in response assessment.
Journal: Breast cancer research and treatment
Published: June 20, 2016
Last Updated: 09/26/2026